Fulcrum Therapeutics Stock Total Asset
| FULC Stock | USD 3.88 0.03 0.78% |
Fulcrum Therapeutics fundamentals help investors to digest information that contributes to Fulcrum Therapeutics' financial success or failures. It also enables traders to predict the movement of Fulcrum Stock. The fundamental analysis module provides a way to measure Fulcrum Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fulcrum Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 257.7 M | 164.9 M |
Fulcrum | Total Asset |
Fulcrum Therapeutics Company Total Asset Analysis
Fulcrum Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Fulcrum Therapeutics Total Asset | 257.69 M |
Most of Fulcrum Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fulcrum Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Fulcrum Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Fulcrum Therapeutics is extremely important. It helps to project a fair market value of Fulcrum Stock properly, considering its historical fundamentals such as Total Asset. Since Fulcrum Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fulcrum Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fulcrum Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Fulcrum Total Asset Historical Pattern
Today, most investors in Fulcrum Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Fulcrum Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Fulcrum Therapeutics total asset as a starting point in their analysis.
Fulcrum Therapeutics Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Fulcrum Total Assets
Total Assets |
|
Based on the latest financial disclosure, Fulcrum Therapeutics has a Total Asset of 257.69 M. This is 96.57% lower than that of the Pharmaceuticals sector and 86.96% lower than that of the Health Care industry. The total asset for all United States stocks is 99.13% higher than that of the company.
Fulcrum Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fulcrum Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fulcrum Therapeutics could also be used in its relative valuation, which is a method of valuing Fulcrum Therapeutics by comparing valuation metrics of similar companies.Fulcrum Therapeutics is currently under evaluation in total asset category among its peers.
Fulcrum Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fulcrum Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fulcrum Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Fulcrum Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Fulcrum Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Fulcrum Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fulcrum Therapeutics' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Suvretta Capital Management, Llc | 2024-09-30 | 1.2 M | Braidwell Lp | 2024-09-30 | 1.1 M | Goldman Sachs Group Inc | 2024-09-30 | 928 K | Deutsche Bank Ag | 2024-06-30 | 849.2 K | D. E. Shaw & Co Lp | 2024-09-30 | 757.7 K | Woodline Partners Lp | 2024-09-30 | 670.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 569.2 K | Northern Trust Corp | 2024-09-30 | 567.7 K | Ra Capital Management, Llc | 2024-09-30 | 10.2 M | Tcg Crossover Management, Llc | 2024-09-30 | 5.2 M |
Fulcrum Fundamentals
| Return On Equity | -0.0737 | ||||
| Return On Asset | -0.0689 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | 0.66 % | ||||
| Current Valuation | (40.43 M) | ||||
| Shares Outstanding | 53.94 M | ||||
| Shares Owned By Insiders | 1.62 % | ||||
| Shares Owned By Institutions | 89.69 % | ||||
| Number Of Shares Shorted | 4.68 M | ||||
| Price To Earning | (1.99) X | ||||
| Price To Book | 0.81 X | ||||
| Price To Sales | 2.61 X | ||||
| Revenue | 2.81 M | ||||
| Gross Profit | (70.44 M) | ||||
| EBITDA | (108.49 M) | ||||
| Net Income | (97.33 M) | ||||
| Cash And Equivalents | 221.79 M | ||||
| Cash Per Share | 4.26 X | ||||
| Total Debt | 10.82 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.49 X | ||||
| Book Value Per Share | 3.80 X | ||||
| Cash Flow From Operations | (90.97 M) | ||||
| Short Ratio | 7.67 X | ||||
| Earnings Per Share | (0.29) X | ||||
| Price To Earnings To Growth | (0.45) X | ||||
| Target Price | 5.29 | ||||
| Number Of Employees | 76 | ||||
| Beta | 2.24 | ||||
| Market Capitalization | 213.06 M | ||||
| Total Asset | 257.69 M | ||||
| Retained Earnings | (509.67 M) | ||||
| Working Capital | 228.52 M | ||||
| Current Asset | 22.54 M | ||||
| Current Liabilities | 3.5 M | ||||
| Net Asset | 257.69 M |
About Fulcrum Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fulcrum Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulcrum Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulcrum Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:Check out Fulcrum Therapeutics Piotroski F Score and Fulcrum Therapeutics Altman Z Score analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 1.317 | Quarterly Revenue Growth 89.909 | Return On Assets (0.07) | Return On Equity (0.07) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.